127 related articles for article (PubMed ID: 9825768)
1. The effects of diminishing albumin binding to some Endothelin receptor antagonists.
Szczepankiewicz BG; Bal RB; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Opgenorth TJ; Hoffman DJ; Borre AJ; Marsh KC; Nguyen BN
Life Sci; 1998; 63(21):1905-12. PubMed ID: 9825768
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
[TBL] [Abstract][Full Text] [Related]
3. Endothelins and endothelin receptor antagonists: binding to plasma proteins.
Wu-Wong JR; Chiou WJ; Hoffman DJ; Winn M; von Geldern TW; Opgenorth TJ
Life Sci; 1996; 58(21):1839-47. PubMed ID: 8637410
[TBL] [Abstract][Full Text] [Related]
4. Unique endothelin receptor binding in kidneys of ETB receptor deficient rats.
Taylor TA; Gariepy CE; Pollock DM; Pollock JS
Am J Physiol Regul Integr Comp Physiol; 2003 Mar; 284(3):R674-81. PubMed ID: 12611392
[TBL] [Abstract][Full Text] [Related]
5. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
[TBL] [Abstract][Full Text] [Related]
6. Direct determination of endothelin receptor antagonist levels in plasma using a scintillation proximity assay.
Dayton BD; Chiou WJ; Opgenorth TJ; Wu-Wong JR
Life Sci; 2000; 66(10):937-45. PubMed ID: 10714894
[TBL] [Abstract][Full Text] [Related]
7. The effect of castration on endothelins, their receptors and endothelin converting enzyme in rat prostate.
Takahashi W; Afiatpour P; Jr Foster HE; Ikeda K; Wada Y; Weiss RM; Latifpour J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):166-76. PubMed ID: 12122504
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
Wu-Wong JR; Dixon DB; Chiou WJ; Sorensen BK; Liu G; Jae HS; Tasker A; von Geldern TW; Winn M; Opgenorth TJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():107S-111S. PubMed ID: 12193066
[TBL] [Abstract][Full Text] [Related]
9. 'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects.
Chiou WJ; Wessale JL; von Geldern T; Opgenorth TJ; Wu-Wong JR
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S48-52. PubMed ID: 11078333
[TBL] [Abstract][Full Text] [Related]
10. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
Yuyama H; Noguchi Y; Fujimori A; Ukai M; Fujiyasu N; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Sep; 498(1-3):171-7. PubMed ID: 15363992
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat.
Saleh MA; Boesen EI; Pollock JS; Savin VJ; Pollock DM
Hypertension; 2010 Nov; 56(5):942-9. PubMed ID: 20823379
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.
Jae HS; Winn M; von Geldern TW; Sorensen BK; Chiou WJ; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 2001 Nov; 44(23):3978-84. PubMed ID: 11689084
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
Wessale JL; Adler AL; Novosad EI; Calzadilla SV; Dayton BD; Marsh KC; Winn M; Jae HS; von Geldern TW; Opgenorth TJ; Wu-Wong JR
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():112S-117S. PubMed ID: 12193067
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity.
Boyd SA; Mantei RA; Tasker AS; Liu G; Sorensen BK; Henry KJ; von Geldern TW; Winn M; Wu-Wong JR; Chiou WJ; Dixon DB; Hutchins CW; Marsh KC; Nguyen B; Opgenorth TJ
Bioorg Med Chem; 1999 Jun; 7(6):991-1002. PubMed ID: 10428367
[TBL] [Abstract][Full Text] [Related]
15. Endothelin binding to NG108-15 cells: evidence for conventional ETA and ETB receptor subtypes and super-high affinity binding components.
Angelova K; Ergul A; Narayan P; Puett D
Cell Mol Biol (Noisy-le-grand); 1996 Dec; 42(8):1243-57. PubMed ID: 8997527
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster.
Honoré JC; Fecteau MH; Wessale JL; D'Orléans-Juste P
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S68-71. PubMed ID: 15838362
[TBL] [Abstract][Full Text] [Related]
17. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats.
De Gottardi A; Shaw S; Sägesser H; Reichen J
J Hepatol; 2000 Nov; 33(5):733-7. PubMed ID: 11097480
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics.
Wu-Wong JR; Dixon DB; Chiou WJ; Opgenorth TJ
J Pharmacol Exp Ther; 1997 May; 281(2):791-8. PubMed ID: 9152387
[TBL] [Abstract][Full Text] [Related]
19. Identification of endothelin receptor subtypes in sheep choroid plexus.
Angelova K; Puett D; Narayan P
Endocrine; 1997 Dec; 7(3):287-93. PubMed ID: 9657064
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.
Rosanò L; Spinella F; Di Castro V; Nicotra MR; Albini A; Natali PG; Bagnato A
Am J Pathol; 2003 Aug; 163(2):753-62. PubMed ID: 12875994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
